
|Videos|June 25, 2017
Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL
Author(s)Eric Smith, MD, PhD
Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
Advertisement
Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) chimeric antigen receptor (CAR) T-cell therapy in B-cell acute lymphoblastic leukemia (B-ALL).
In a study of adult patients with relapsed/refractory B-ALL, investigators aimed to identify patients who would benefit from 19-28z CAR T-cell therapy, measured by durable long-term survival and reduced toxicities.
Results showed that the complete remission rate was 85% in this typically poor-prognosis setting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5



































